• Radiation Oncology Journal
• /
• 제6권2호
• /
• pp.169-176
• /
• 1988

1979년부터 1985년까지 서울대학교병원 치료방사선과에서 외부 방사선조사를 시행한 15명의 뇌하수체상부 배아세포종(전이송과선종) 환자에 대한 후향적 분석을 시행하였다. 생존자의 추적기간은 $30\~91$개월이었다. 10명의 환자는 방사선치료 전 조직학적으로 진단되었으며 나머지 5명은 조직학적 진단이 없이 방사선치료를 시행하였단 조직학적으로 진단된 9명중 배아세포종 환자 6명은 전뇌와 척추에 3명은 전뇌 조사를 시행하였다. 혼합 배아세포종 및 종양 marker양성인 5명의 환자 중 2명은 전뇌, 그리고 1명은 원발병소 부위에만 방사선치료를 시행하였다. 총 방사선량은 원발병소에 $5,000\~5,500 cGy$, 전뇌에 $3,000\~4,400 cGy$ 그리고 척추에 >$1,300\~3,000 cGy$였다. 상기 그룹 14명의 환자에서 원발병소는 완전 관해 되었으며 척추실패는 관찰되지 많았다. 조직학적 진만이 없고 marker의 상승이 없었던 한 환자에서 전뇌 방사선조사를 시행하였으나 원발병소의 완전관해 없이 척추 재발이 발생하였다. 방사선치료는 뇌하수체상부 배아세포종에 유효한 치료방법이며 신경 내분비학적 양상과 함께 조직학적 진단이 불가능한 경우에 있어서 소량의 방사선치료 후 관해정도 관찰은 이후의 치료방향설정에 유용한 수단으로 이용될 수 있다.

• 한국임상수의학회지
• /
• 제19권2호
• /
• pp.256-259
• /
• 2002

A 39 kg, 7-year-old male Labrador Retriever dog with a 3-month history of epistaxis, sneezing, and nasal discharge was referred to the Veterinary Medical Center of the Tokyo University. On the plain X-ray and computed tomography (CT) of the head showed increased density of the soft tissue in the left nasal cavity and the tumor infiltrated to nasal septum. The tumor mass removed by rhinotomy. Histopathological examination of the mass revealed adenocarcinoma. Four weeks after the surgery, the radiation therapy was performed twice a week for f weeks. 4 months after surgery, the dog had a recurrence in nasal cavity and administered carboplatin 300 mg/$m^2$ twice. However, the tumor had no response to chemotherapy, additional surgery and additional radiation therapy, and the dog was euthanized at the owner's request. At necropsy, metastatic proliferation was confirmed in the lung, lymph nodes and nasal cavity.

• 대한핵의학회지
• /
• 제36권4호
• /
• pp.209-223
• /
• 2002

By considering the biological properties of a tumor, it should be possible to realize better results in cancer therapy. PET imaging offers the opportunity to measure tumor growth non-invasively and repeatedly as an early assessment of response to cancer therapy. Measuring cellular growth instead of energy metabolism showed offer significant advantages in evaluating therapy. Thymidine and its derivative nucleoside compounds can be changed to mono, di- and tri- phosphate compounds by thymidine kinase and then be incorporated into DNA. Their bindings are increased in highly proliferating cells due to the high DNA synthesis rate. To evaluate cell proliferation, many kinds of thymidine and uridine derivatives have been labeled with positron emitter and radioactive iodine. Compared to radiopharmaceuticals which have radioisotope labeled base ring such as pyirmidine, the radiopharmacuticals which have radioisotope labeled sugar ring are more stable in vivo and have metabolic resistance. The biological properties such as DNA incorporation ratios are highly dependent on their chemical structures and metabolic processes. This overview describes synthesis of radiopharmaceuticals and their biological properties for imaging of tumor cell proliferation.

• Radiation Oncology Journal
• /
• 제5권2호
• /
• pp.149-155
• /
• 1987

전산화 단층촬영 (CT)은 진단 분야 뿐 아니라 방사선 치료 계획 및 치료효과의 추적 등 치료분야에 까지 광범위하게 사용되고 있다. 그러나 환자의 체위가 치료시와는 다름으로 얻어진 영상이 치료시의 영상과는 차이가 있으며, 삼차원적인 치료면적의 계산이 곤란할 뿐 아니라 조영제를 사용함으로 생길 수 있는 선량계산의 오라 및 정확한 조사야가 표현되지 많음으로 병소 및 중요 정상장기의 선량 측정이 정확하지 못한점 등의 단점이 없다. 저자들은 1986년 5월 1일부터 1987린 4월 30일까지 영남대학병원 치료방사선과에서 치료받은 총 365명의 환자 중 일반 CT의 단점을 보완한 치료용 CT와 종래의 simulation을 병행한 106명의 치료계획을 비교 분석하여 다음과 같은 결과를 얻었다. 치료용 CT후 두경부 암 환자의 $47\%$, 흉부암 환자의 $79\%$, 복부암 환자의 $63\%$에서 치료계획의 변경이 있어 치료용 CT가 두경부암, 흉부암, 복부암에서 거의 철수적임을 시사하였다. 그러나 직장암, 자궁경부암에서는 추가치료의 조사야의 측정 및 선량계산 이외의 전예에서 치료계획의 변경이 없었다. 선량분포의 비교측정에서는 윤곽만을 사용한 종래의 선량계산이 CT를 사용한 경우에 비해서 두경부암에서는 평균 $20\%$, 흉부암, 복부암에서는 약 $10\%$의 차이를 보여 전례에서 CT보다 과측정 되었음을 보여 종래의 윤곽만을 사용한 치료계획시의 저선량 조사에 대한 보정이 필요함을 시사하였다.

• 대한방사선치료학회지
• /
• 제4권1호
• /
• pp.53-57
• /
• 1990

• IMMUNE NETWORK
• /
• 제21권3호
• /
• pp.23.1-23.16
• /
• 2021

Chemokines are key factors that influence the migration and maintenance of relevant immune cells into an infected tissue or a tumor microenvironment. Therefore, it is believed that the controlled administration of chemokines in the tumor microenvironment may be an effective immunotherapy against cancer. Previous studies have shown that CCL3, also known as macrophage inflammatory protein 1-alpha, facilitates the recruitment of dendritic cells (DCs) for the presentation of tumor Ags and promotes T cell activation. Here, we investigated the role of CCL3 in regulating the tumor microenvironment using a syngeneic mouse tumor model. We observed that MC38 tumors overexpressing CCL3 (CCL3-OE) showed rapid regression compared with the wild type MC38 tumors. Additionally, these CCL3-OE tumors showed an increase in the proliferative and functional tumor-infiltrating T cells. Furthermore, PD-1 immune checkpoint blockade accelerated tumor regression in the CCL3-OE tumor microenvironment. Next, we generated a modified CCL3 protein for pre-clinical use by fusing recombinant CCL3 (rCCL3) with a non-cytolytic hybrid Fc (HyFc). Administering a controlled dose of rCCL3-HyFc via subcutaneous injections near tumors was effective in tumor regression and improved survival along with activated myeloid cells and augmented T cell responses. Furthermore, combination therapy of rCCL3-HyFc with PD-1 blockade exhibited prominent effect to tumor regression. Collectively, our findings demonstrate that appropriate concentrations of CCL3 in the tumor microenvironment would be an effective adjuvant to promote anti-tumor immune responses, and suggest that administering a long-lasting form of CCL3 in combination with PD-1 blockers can have clinical applications in cancer immunotherapy.

• 대한한방내과학회지
• /
• 제12권2호
• /
• pp.96-112
• /
• 1991

Attempts were made to see the antitumor effects of Sigbunhwan widely used in Oh-jug(五積) employing tumor cells Lines such as K562 derived from erythroleukemia, Raji from lympoma and MO-4 from blastogenic tumor. Different concentrations of Sigbunhwan and combined therapy of Sigbunhwan and Bigihwan were treated to those tumor cells lines and then live cells were counted by Trypan blue assay and $^{3}H-Thymidine$ uptake assay. The results obtained were as follows. 1. $^{3}H-Thymidine$ uptake of various tumor cells lines when treated with high concentrations of Sigbunhwan for 48hours showed that the rate of DNA synthesis decreased 76% to 90% by the treatment of 1% Sigbunhwan but this inhibition was rather decreased when Sigbunhwan concentration was increased to 10, 15 and 20%.(Fig 3) 2. When Sigbunhwan was combined with Bigihwan which was also an antitumor drug, the effectiveness of tumor cells dealth was somewhat inceased showing a generally similar pattern to that of Bigihwan alone used.(Fig 4) This combination therapy also showed that higher concentrations of antitumor agent were no more·effective or rather harmful according to the tumor cells lines having different growth rate.(Fig 5,6) 3. The antitumor effects of combined Sigbunhwan and Bigihwan was decreased if the concentrations of this combination therapy was increased to 10 times showing relatively sluggish decrease in K562 and MO-4 but a sharp inhibitory effect in Raji which grows slowly.(Fig 7). 4. When Sigbunhwan was treated at low concentrations, K562 was more inhibited by 0.75% to 1.0% of Sigbunhwan while Raji was more inhibited by 0.25% to 0.5% of that.(Fig 8) 5. When Sigbunhwan was treated together with Bigihwan at low concentrations, the tumor cells death rate was 75% to 89% in Baji, 31% to 95% in MO-4 and 41 to 89% in K562, showing this combination therapy was more effect to Raji derived from lymphoma.(Fig 9) 6. The number of live tumor cells was correlated with optical density of MTT assay when measured with 2% Sigbunhwan treatment to tumor cells lines for 24 hours.(Fig 10) 7. 7 days treatment of 0.25% Sigbunhwan was compared with one day treatment of 1% suggesting long term treatment more effective.(Fig 11)

• Radiation Oncology Journal
• /
• 제2권2호
• /
• pp.287-297
• /
• 1984

The normal intracranial structures are relatively resistant to therapeutic radiation, but may react adversely in a variety of ways, and the damage to nerve tissue may be slow in making its appearance, and once damage has occured the patient recovers slowly and incompletly. Therefore, it is important to consider the possibility of either recurrent tumor or late adverse effect in any patient who has had radiotherapy. The determination o( rnorphological/pathological correlation is very important to the therapeutic radiologist who uses CT scans to define a treatment volume, as well as to the clinician who wishes to explain the patient's clinical state in terms of regress, progression, persistence, or recurrence of tumor or radiation-induced edema or necrosis, The authors are obtained as following results ; 1. The field size(whole CNS, large, intermediate, small field) was variable according to the location and extension of tumor and histopathologic diagnosis, and the tatal tumor dose was 4,000 to 6,000 rads except one of recurred case of 9,100 rads. The duration of follow up CT scan was from 3 months to 5 year 10 months. 2, The histopathologic diagnosis of 9cases were glioblastoma multiforme(3 cases), pineal tumor (3), oligodendroglioma (1), cystic astrocytoma (1), pituitary adenoma (1) and their adverse effects after radiation therapy were brain atrophy (4 cases) , radiation necrosis(2), tumor recurrence with or without calcification (2), radiation·induced infarction (1). 3. The recurrent symptoms after radiation therapy of brain tumor were not always the results of regrowth of neoplasm, but may represent late change of irradiated brain. 4. It must be need that we always consider the accurate treatment planning and proper treatment method to reduce undesirable late adverse effects in treatment of brain tumors.

• Radiation Oncology Journal
• /
• 제24권2호
• /
• pp.149-155
• /
• 2006

수막에 발생하는 혈관주위세포종은 경질막에 기초한 드문 종양으로서 국소재발과 함께 신경축이나 신경외 장소로 원격전이를 일으킬 수도 있다. 저자들은 수막에 발생한 혈관주위세포종 환자 2예에서 수술 전 방사선치료와 수술 후 방사선치료를 각각 경험하였기에 방사선치료의 역할에 관한 문헌고찰과 함께 보고하고자한다. 첫 번째 증례는 41세 남자로 3개월 동안 두통과 우측 반부전마비가 있었다. 1차 수술과 2차 수술 시 종양은 거의 제거할 수 없었고 수막 혈관주위세포종으로 진단되었다. 수술 전 방사선치료를 좌측 전두두정부의 큰 잔여종양에 일 회에 1.8 Gy씩 31회에 걸쳐 총 55.8 Gy를 조사하였다. 방사선치료 후 CT검사상 종양은 현저하게 크기가 줄었고 방사선치료 후 6개월에 시행한 3차 수술 시 잔여 종양의 크기는 $2{\times}2cm$로 완전히 제거되었다. 추적 CT검사상 국소재발의 소견은 없었고, 1차 수술 후 4년 10개월 동안 원격 전이 없이 생존하고 있다. 두 번째 증례는 45세 여자로 갑작스러운 두통과 시력 장애로 수막종이 의심되어 종양제거수술을 받았는데 조직 검사상 우측 전두엽에 발생한 혈관주위세포종으로 진단되었으며 시상동을 침습한 소견을 보였으나 완전히 제거되었다. 국소재발을 줄이기 위해 수술 후 방사선치료가 의뢰되었고 방사선치료는 우측전두엽 부위에 일 회에 1.8 Gy씩 30회에 걸쳐 총 54 Gy를 조사하였다. 수술 후 5년 동안 국소 재발이나 원격전이 없이 정상적인 활동을 유지하면서 생존하고 있다.

• Journal of Korean Neurosurgical Society
• /
• 제59권6호
• /
• pp.597-603
• /
• 2016

Introduction : Perioperative irradiation is often combined with spine tumor surgery. Radiation is known to be detrimental to healing process of bone fusion. We tried to investigate bone fusion rate in spine tumor surgery cases with perioperative radiation therapy (RT) and to analyze significant factors affecting successful bone fusion. Methods : Study cohort was 33 patients who underwent spinal tumor resection and bone graft surgery combined with perioperative RT. Their medical records and radiological data were analyzed retrospectively. The analyzed factors were surgical approach, location of bone graft (anterior vs. posterior), kind of graft (autologous graft vs. allograft), timing of RT (preoperative vs. postoperative), interval of RT from operation in cases of postoperative RT (within 1 month vs. after 1 month) radiation dose (above 38 Gy vs. below 38 Gy) and type of radiation therapy (conventional RT vs. stereotactic radiosurgery). The bone fusion was determined on computed tomography images. Result : Bone fusion was identified in 19 cases (57%). The only significant factors to affect bony fusion was the kind of graft (75% in autograft vs. 41 in allograft, p=0.049). Other factors proved to be insignificant relating to postoperative bone fusion. Regarding time interval of RT and operation in cases of postoperative RT, the time interval was not significant (p=0.101). Conclusion : Spinal fusion surgery which was combined with perioperative RT showed relatively low bone fusion rate (57%). For successful bone fusion, the selection of bone graft was the most important.